Why Solventum (SOLV) is a Top Stock for the Long-Term

Zacks presents its Focus List, a curated portfolio of 50 stocks selected based on positive earnings estimate revisions. The list has historically outperformed the S&P 500, with cumulative returns of 2,519.23% since February 1996 compared to the S&P's 854.95%. The methodology relies on the Zacks Rank system, which evaluates stocks based on earnings consensus among analysts. Solventum (SOLV), a healthcare company spun off from 3M, is highlighted as a recent addition that has gained 29.89% since April 2024.